Radiopharm Theranostics (ASX:RAD) Net Issuance of Preferred Stock : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Radiopharm Theranostics's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. The number is 0, which means that Radiopharm Theranostics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Radiopharm Theranostics's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Radiopharm Theranostics Net Issuance of Preferred Stock Historical Data

The historical data trend for Radiopharm Theranostics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Net Issuance of Preferred Stock Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Net Issuance of Preferred Stock

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Net Issuance of Preferred Stock	-	-	-	-	-

Radiopharm Theranostics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Radiopharm Theranostics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (ASX:RAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

RDPTF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines